http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2553510-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_871cab24a8d3fd854178fb9e57dfffb1 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 |
| filingDate | 2013-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95665fb80b272b8553ebeb40ed209a66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daec7ef0dd5d9dd11195f56461d47a69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e6468d399601125b348ab0f9380ffb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0051b298b090680c9fc6ced2d976c308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b96bb7a5666aba3105d93c2190736c01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_418ca5dd77bff0e02f703abc1f31ec47 |
| publicationDate | 2015-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2553510-C1 |
| titleOfInvention | Method of treating proliferative diabetic retinopathy complicated by haemophthalmia with using intraoperative fluorescein angiography |
| abstract | FIELD: medicine. n SUBSTANCE: method involves a vitrectomy, a detachment and a removal of a posterior hyaloids of a vitreous body, and a retinal laser endocoagulation. After transparency of the vitreal cavity structures is recovered, a fluorescein angiography (FAG) is performed. If the FAG findings enable visualising hyperfluorescence close to a vascular arcade and a macular area, the retinal laser endocoagulation is performed in this area at wave length 532 nm, pulse length 0.1 s, spot diameter 100 mcm, power 70-100 mWt, in a number of 100-200 coagulates. If the hyperfluorescence is found to be outside the vascular arcades, then the retinal laser endocoagulation is performed in this area at wave length 532 nm, pulse length 0.2 s, spot diameter 200-400 mcm, power 150-250 mWt, in a number of 400-500 coagulates. n EFFECT: reducing the amount of total laser energy that enables reducing complications, such as recurrent haemophthalmia, progressive proliferation, developing retinal detachment. n 4 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2729031-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2716484-C1 |
| priorityDate | 2013-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.